Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report) – Investment analysts at Brookline Capital Management raised their FY2026 EPS estimates for Radiopharm Theranostics in a research note issued to investors on Wednesday, October 22nd. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($2.25) per share for the year, up from their prior estimate of ($4.81). Brookline Capital Management has a “Buy” rating and a $18.00 price target on the stock. Brookline Capital Management also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($2.38) EPS.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.00.
Radiopharm Theranostics Stock Performance
NASDAQ RADX opened at $5.28 on Monday. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $50.82. The stock’s 50-day moving average is $6.14 and its two-hundred day moving average is $5.10.
Hedge Funds Weigh In On Radiopharm Theranostics
An institutional investor recently bought a new position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. bought a new stake in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned 0.10% of Radiopharm Theranostics as of its most recent SEC filing.
About Radiopharm Theranostics
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
Featured Articles
- Five stocks we like better than Radiopharm Theranostics
- The Role Economic Reports Play in a Successful Investment Strategy
- Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- Short Selling – The Pros and Cons
- Are These 3 Beaten-Down Stocks Ready to Rebound?
- What is the Nikkei 225 index?
- Does the Trump-Induced Quantum Stock Rally Have Legs?
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
